Generic Cabometyx Availability
Last updated on Oct 9, 2024.
Cabometyx is a brand name of cabozantinib, approved by the FDA in the following formulation(s):
CABOMETYX (cabozantinib s-malate - tablet;oral)
-
Manufacturer: EXELIXIS INC
Approval date: April 25, 2016
Strength(s): EQ 20MG BASE [RLD], EQ 40MG BASE [RLD], EQ 60MG BASE [RLD]
Has a generic version of Cabometyx been approved?
No. There is currently no therapeutically equivalent version of Cabometyx available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cabometyx. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
C-met modulator pharmaceutical compositions
Patent 10,034,873
Issued: July 31, 2018
Inventor(s): Wilson Jo Ann & Shah Khalid
Assignee(s): Exelixis, Inc.Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.
Patent expiration dates:
- July 18, 2031✓
- July 18, 2031
-
C-Met modulator pharmaceutical compositions
Patent 10,039,757
Issued: August 7, 2018
Inventor(s): Wilson Jo Ann & Shah Khalid
Assignee(s): Exelixis, Inc.Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.
Patent expiration dates:
- July 18, 2031✓
- July 18, 2031
-
Patent 11,091,439
Patent expiration dates:
- January 15, 2030✓
- January 15, 2030
-
Patent 11,091,440
Patent expiration dates:
- January 15, 2030✓
- January 15, 2030
-
Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
Patent 11,098,015
Issued: August 24, 2021
Inventor(s): Brown Adrian St. Clair & Lamb Peter & Gallagher William P.
Assignee(s): Exelixis, Inc.Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide.
Patent expiration dates:
- January 15, 2030✓
- January 15, 2030✓
- January 15, 2030✓
- January 15, 2030✓
- January 15, 2030
-
Patent 11,298,349
Patent expiration dates:
- February 10, 2032✓
- February 10, 2032
-
Patent 7,579,473
Patent expiration dates:
- August 14, 2026✓✓
- August 14, 2026
-
C-met modulators and method of use
Patent 8,497,284
Issued: July 30, 2013
Inventor(s): Bannen Lynne Canne & Chan Diva Sze-Ming & Chen Jeff & Dalrymple Lisa Esther & Forsyth Timothy Patrick & Huynh Tai Phat & Jammalamadaka Vasu & Khoury Richard George & Leahy James William & Mac Morrison B. & Mann Grace & Mann Larry W. & Nuss John M. & Parks Jason Jevious & Takeuchi Cr
Assignee(s): Exelixis, Inc.The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Patent expiration dates:
- September 24, 2024✓
- September 24, 2024✓
- September 24, 2024✓
- September 24, 2024
-
(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Patent 8,877,776
Issued: November 4, 2014
Inventor(s): Brown Adrian St. Clair & Lamb Peter & Gallagher William P.
Assignee(s): Exelixis, Inc.Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane -1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-ffuorophenyl)cyclopropane-1,1-dicarboxamide.
Patent expiration dates:
- October 8, 2030✓✓✓
- October 8, 2030
-
C-met modulator pharmaceutical compositions
Patent 9,724,342
Issued: August 8, 2017
Inventor(s): Wilson Jo Ann & Shah Khalid
Assignee(s): Exelixis, Inc.Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.
Patent expiration dates:
- July 9, 2033✓
- July 9, 2033
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- January 22, 2024 - FOR THE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA, AS A FIRST-LINE TREATMENT IN COMBINATION WITH NIVOLUMAB
- September 17, 2024 - TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (DTC) THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY OR INELIGIBLE
- January 14, 2026 - INDICATED FOR TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
- September 17, 2028 - THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (DTC) THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY OR INELIGI
More about Cabometyx (cabozantinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (12)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
